Last reviewed · How we verify
Intensive glycemic control
At a glance
| Generic name | Intensive glycemic control |
|---|---|
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Musculoskeletal
- Infections
- Nervous system
- General Disorders
- Gastrointestinal Disorders
- Injury
- Respiratory
- Skin
- Eye Disorders
- Psychiatric
- Investigations
- Renal
Key clinical trials
- Individualized Medical Nutrition Therapy in Adults With Type 2 Diabetes Mellitus (NA)
- Microbiome and Health Indicators in People With Obesity, Prediabetes and Type 2 Diabetes Undergoing a Lifestyle Intervention (NA)
- Intensive Diet and Physical Activity on Diabetes (NA)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- Impact of Metabolic Health on Sperm Epigenetic Marks in Humans (NA)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
- CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS (PHASE4)
- A Comprehensive Community Approach for Diabetes Prevention and Care for a Vulnerable Population in Galveston (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intensive glycemic control CI brief — competitive landscape report
- Intensive glycemic control updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI